Edgewise Therapeutics, Inc.
EWTX · XNASCIK 1710072fmd_0CTHGPE2T0Q69B77VK70PB5RYNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 15 | 32 | 54 | 91 | 127 | 151 |
| Total operating expenses | 17 | 43 | 72 | 114 | 159 | 191 |
| Operating income | (17) | (43) | (72) | (114) | (159) | (191) |
| Income before taxes | – | – | – | (100) | (134) | (168) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (100) | (134) | (168) |
| Net income | (17) | (43) | (68) | (100) | (134) | (168) |